Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Indoor cultivation biz bows to Airoclean 420. Tru-Infusion is a massive indoor cultivation company in Arizona (over 300,000 sq. ft.), and they have switched to Airoclean 420 for all of their 79 facilities statewide.
Applied UV Continues Cannabis Market Expansion
June 23 2022 - 08:00AM
Business Wire
Tru Infusion Places Significant Order
Largest Indoor Cannabis Cultivator in Arizona
Airoclean 420 by Sterilumen (AUVI subsidiary) dramatically improves your crop yield by purifying the air in your grow environment. With our Patented Photocatalytic Oxidation technology (PCO), Airoclean 420 traps and destroys all airborne powdery mildew and other fungal diseases. Airoclean 420 is far more effective than HEPA filters, which use a “screen door” design circulating harmful pathogens and contaminants back into the air.
Multimedia
https://airoclean420.com/
https://ih.advfn.com/stock-market/NASDAQ/applied-uv-AUVI/stock-news/88435639/applied-uv-continues-cannabis-market-expansion
David J. Lawson, Tru Infusion COO, stated, “Nature Wonder, dba Tru Infusion, has become one of Arizona’s largest indoor cultivating companies. With multiple facilities spread throughout the state, we have in-excess of 300,000 sq. ft underroof. Our total flower canopy is expanded even further because we utilize multi-tier racks in 75% of our flower rooms. This means that the complexity of maintaining consistent room environments becomes a greater challenge due to the micro-climates with ceiling heights ranging between 16 feet and 22 feet. When looking at the cubic feet of space within our flower rooms, we looked to replace our earlier vendor. While they will remain nameless, I will say their solution worked fine in our single tier rolling table environments with 12–13-foot ceilings. The Airoclean 420 however, allowed us the ability to purify our air in the much larger grow rooms. After nearly a year and a half we have had no issues with the units at all – and we have over 100 units installed. As a result, you have a happy customer with future intentions to acquiring even more units for our planned expansions over the next 2 years.”
Past is prologue. September 1, 1997.
US$10M in 1997 dollars translates to more than US$18M in 2022 dollars.
See prior post #144 for "the rest of the story," and why Applied UV, Inc, is now guided by arguably one of the best CEOs & Directors in the field, hands down, viz., John F. Andrews.
$AUVI
$CSX
Get ready.
Unlike not a few competing machines, Airocide purifies the air "without producing ozone or other harmful byproducts."
Ozone is O3, whereas O2 is pure Oxygen. O3 is an intense oxidizer created when Oxygen (O2) is subjected to high-energy elecrical discharges, and can damage the body's respiratory system if breathed; in sufficient concentrations or over time in lesser concentrations, O3 can severely impair the respiratory system.
"Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo-catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts."
$AUVI
Powerhouse J.F. Andrews joining as CEO signals growth, significant growth is at hand. With a business background as deep and successful as his, the highly talented John Andrews would not have accepted the offer unless the technology were top of the line and the opportunity for immense rewards were irresistible. Get ready.
John F. Andrews, CEO & Director of Applied UV, Inc.
1993 GTE "John joined CSX from GTE (General Telephone & Electronics) where he held positions as Vice President & General Manager of several business units serving the health, government, and telecommunications industries. During his career at GTE, he also held positions in engineering , planning, operations, and finance."
https://www.deepdyve.com/lp/association-for-computing-machinery/peopleware-emerging-roles-and-responsibilities-an-interview-with-john-a2zTrEMhL2
1997 Chief Information Officer & Senior VP at CSX Corp. and President for CSX Technology, Inc.
[CSX Corp. Current market cap $62.1B]
https://www.deepdyve.com/lp/association-for-computing-machinery/peopleware-emerging-roles-and-responsibilities-an-interview-with-john-a2zTrEMhL2
January 2003: CEO (John F. Andrews) of Giga Info Group (Nasdaq: GIGA), Cambridge, Mass. Revenues $69.8 million, 275 employees. Andrews spearheads the sale of Giga to Forrester Group (Nasdaq: $FORR) for $60 million.
https://www.wsj.com/articles/SB1043162630331757384
Nov 08, 2004: "ShipXpress, Inc, a leading supplier of supply chain management application software and services, appoints John F. Andrews as Chairman of the Board of Directors. Andrews' responsibilities will include guiding new business development among large enterprise clients."
https://www.prweb.com/releases/2004/11/prweb175362.htm
SEC: "From 2011 to 2016, Mr. Andrews served as a member of the Board of Directors and as Head of Sales of ShipXpress Inc., a SAAS based logistics software company. In this role, he was a key principal in the process of the sale of the company to General Electric on September 1, 2016."
August 30, 2016: GE (General Electric) Transportation (NYSE: $GE), the world’s leading producer of rail and transportation-related products and offerings, announced its acquisition of ShipXpress, a top provider of cloud-based software solutions that enable transportation, industrial, and commodities businesses to efficiently operate with supply chain partners.
https://www.ge.com/news/press-releases/ge-acquires-top-supply-chain-software-provider-shipxpress-expand-digital-rail
April 03, 2017: Duos Technologies Group, Inc. Appoints John F. Andrews as Chief Operating Officer and Executive Vice President
"Mr. Andrews is a senior executive with a demonstrated record of success in achieving revenue, profit and business goals in start-up and large corporate environments for both public and private companies. His business experience has spanned multiple industries including telecommunications, healthcare, transportation and information technology."
https://www.marketscreener.com/quote/stock/DUOS-TECHNOLOGIES-GROUP-100152623/news/Duos-Technologies-Group-Inc-Appoints-John-F-Andrews-as-Chief-Operating-Officer-and-Executive-Vice-35156649/
Chief Executive Officer & Resolution Director at EBC, Inc., Chief Executive Officer & Director at Varsity Media Group, Inc., Chief Executive Officer at Evans Data Corp., Chief Operating Officer & Executive Vice President at Duos Technologies Group, Inc. and President & Chief Operating Officer of Duos Technologies, Inc. (a subsidiary of Duos Technologies Group, Inc.), Chief Information Officer & Senior VP at CSX Corp. and President for CSX Technology, Inc. (a subsidiary of CSX Corp.), Chief Technology Officer of KyckGlobal, Inc., Chief Executive Officer at Giga Information Group, Inc., Director & Head-Sales at ShipXpress, Inc. and Chief Operating Officer of Girl Scout of Gateway Council, Inc.
$AUVI
Read our CEO's remarkable bio & celebrate your decision to accumulate and John F. Andrew's decision to take the reins along with his team. No one could ask for a more accomplished and skillful executive to take Applied UV, Inc. to heights beyond even most bullish expectations while maintaining balance sheet economies.
AUVI CEO & Director John F. Andrews (as of April 8, 2022) is a seasoned and accomplished executive with more than 30 years of senior leadership experience in telecom and technology companies -- public and private.
Andrews was CEO of several public companies and also started and founded companies from ground zero. His experience includes leading three companies to strategic exits (two private and one public), raising more than one hundred million dollars of public and private capital, managing numerous mergers and acquisitions,leading companies through explosive growth as well as rightsizing, and being recruited to turn around stalled companies,.
Mr. Andrews was CEO and Co-founder of Trinity IT Services LLC and CEO of TrekSecure LLC. He was also Chairman and EVP of ShipXpress which was acquired by GE. He was CEO of Giga (Nasdaq: GIGA) where he led the company’s sale to Forrester Research (Nasdaq: FORR). He was CEO of e-Medsoft which went public.
Fortune 300
Andrews was Senior Vice President (SVP) and Chief Information (CIO) of giant CSX Corp. (Nasdaq: CSX), a Fortune 300 firm where he managed thousands of employees. During his tenure at CSX, he was credited in achieving over five hundred million dollars in operating expense reductions through his visionary and portfolio technology projects. As CIO, he received several industry awards to include CIO of the Year from Information Week and Top Industry Visionary from Computerworld.
While at CSX, Andrews also consulted with Sun Microsystems (Nasdaq: SUNW) on the development of JAVA. Prior to CSX, Andrews held executive positions with telecom giant GTE, to include division CIO, President Government Information Systems and President Healthcare Information Systems.
Mr. Andrews earned an M.B.A. from the University of Puget-Sound, Seattle WA, and a B.A. in Business Administration and Finance from Whitworth University, Spokane WA.
Source:
https://www.citybiz.co/article/243744/john-f-andrews-joins-applied-uv-as-chief-executive-officer/
$AUVI
O/S 12.96M Float 7.32M MC 29.8M per closing price @ $2.30/sh (Marketwatch data 06-21-2022). What with the pressing need for AUVI's advanced differentiated purification technologies eradicating pathogens including mold, the interest of big names, a dynamic seasoned new CEO (former Fortune 500), not to mention a a stock buyback program, any larger outfit could swallow this company without so much as a belch.
https://www.citybiz.co/article/243744/john-f-andrews-joins-applied-uv-as-chief-executive-officer/
Yahoo Finance
Wall Street Reporter
June 9, 2022
"Advancing Next Wave of Multi-Billion Dollar Growth Opportunities in Metaverse, HealthTech Wearables, and Clean Air Technologies
"AUVI CEO John Andrews commented: “Improving the quality of indoor air in all public indoor places, specifically government hospitals, protecting the facilities, staff and the patients who frequent them from dangerous pathogens is at the center of efforts by governments globally. With the implementation of these government guidelines and standards for business to use to improve indoor air quality beginning, our air purification solutions are the best-in-class tools to use as the world’s economy begins to re-open, post pandemic.”
$AUVI
Stakes high. AUVI Airocide™ protects "massive investments" including but not limited to wineries, food processors, healthcare and hospitality industries from all molecular air-borne pathogens including mold.
Cellarius has been a European Distributor of the patented, disruptive Airocide™ product for over 8 years deploying our FDA Class II Listed device, which was developed for use by NASA, that utilizes a combination of photo-catalytic oxidation, our proprietary chemical process and UVC within its reaction chamber which is a clear differentiator in air purification.
This unique process destroys all carbon-based molecular air borne pathogens that pass through the chamber including mold, which, left untreated, negatively impacts the massive investments made by wineries in the wine barrel rooms and post-harvest facilities where inventories are stored.
Cellarius sells Airocide™ in multiple business end user cases including, food processing, cannabis, wineries, hospitality, and healthcare. Airocide’s patented technology leads the world in air purification and is chosen by globally recognized brands due to this product differentiation."
And lest we forget:
June 14, 2022 "Applied UV Installs Patented LumiCide Surface Disinfection Solution into NYC’s Mt. Sinai Medical Center Morningside One of the World’s Prestigious Hospitals
"Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (“UVC”) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announces that its wholly owned subsidiary SteriLumen has just installed its patented LumiCide Surface and Drain UVC Disinfecting Systems initially, in 17 patient rooms within the world renowned Mt. Sinai Medical Center Morningside. Mount Sinai Morningside, formerly known as Mount Sinai St. Luke's, is a teaching hospital located in the Morningside Heights neighborhood of Manhattan in New York City."
https://ih.advfn.com/stock-market/NASDAQ/applied-uv-AUVI/stock-news/88360011/applied-uv-installs-patented-lumicide-surface-disi
$AUVI
Buy opp from misinterpreting PR? Oenology is the science of wine. The company Cellarius, aptly named, are oenologists who serve the needs of vitculturists (grape growers) and winemakers---from the grape to the pressing to the fermentation to the cask for aging to the bottling and steps in between.*
Cellarius is based is based in Szigetvár, an ancient town in Hungary, member of the EU. Gooogle translation of their website linked below.
Dark underground wine cellars of winemakers help maintain environmental conditions critical for wine making. And most people know that cellars are prone to mold issues. Consider that the vintner or vintners in question are aware they would telegraph serious mold issues with an announcement of a big dollar number contract with AUVI. However, as the information is material, it still needs be PR'ed. Hence, "substantial order"
*From the Cellarius website [Gooogle translation from Hungarian to English)
Laboratory
Examination of more than 60 kinds of analytical parameters, wine aroma and taste components, state-of-the-art laboratory equipment.
Research + development
Constant research and innovation is an essential part of our company's operations. The Nutrioak product family, new maturation technology solutions, research on Hungarian oak (for the barrels in the aging process).
https://cellarius.hu/ (Hungarian)
Translation to English
https://cellarius-hu.translate.goog/?_x_tr_sl=hu&_x_tr_tl=en&_x_tr_hl=en
-Cellarius Ltd. is one of the 1000 fastest growing companies in Europe!
by Cellarius | March 31, 2022
https://cellarius-hu.translate.goog/cellarius-kft-europa-1000-leggyorsabban-novekvo-vallalatai-egyike/?_x_tr_sl=hu&_x_tr_tl=en&_x_tr_hl=en
$AUVI
https://ih.advfn.com/stock-market/NASDAQ/applied-uv-AUVI/stock-news/88412681/applied-uv-receives-substantial-order-from-europea
Direct link to Cellarius (AUVI distributor):
Cellarius (German language)
https://cellarius.hu/
From 6-21-2022 AUVI PR
"John F. Andrews, Applied UV’s CEO and Director stated, “Cellarius is one of our leading European Distributors. We are extremely grateful for their continued sales of our Airocide™ air purification suite.
We applaud their continued success which is attributable to and is further testament to the efficacy, ease of use and effectiveness of our air purification solutions as the world not only reopens from the throws of this 3-year pandemic, but more importantly, prepares against future airborne pathogens enabling business, schools, governments, and facilities to remain open.
This contract further demonstrates the strong global brand recognition and the growing end user business case our suite of Airocide™ air purification product offerings commands. The trust European companies have placed with our Distribution Partner Cellarius further underscores our commitment to provide best in class air purification solutions that help protect facilities, staffs, and consumers globally."
https://ih.advfn.com/stock-market/NASDAQ/applied-uv-AUVI/stock-news/88412681/applied-uv-receives-substantial-order-from-europea
$AUVI
6-21 PR excerpt: "Cellarius has been a European Distributor of the patented, disruptive Airocide™ product for over 8 years deploying our FDA Class II Listed device, which was developed for use by NASA, that utilizes a combination of photo-catalytic oxidation, our proprietary chemical process and UVC within its reaction chamber which is a clear differentiator in air purification. This unique process destroys all carbon-based molecular air borne pathogens that pass through the chamber including mold, which, left untreated, negatively impacts the massive investments made by wineries in the wine barrel rooms and post-harvest facilities where inventories are stored. Cellarius sells Airocide™ in multiple business end user cases including, food processing, cannabis, wineries, hospitality, and healthcare. Airocide’s patented technology leads the world in air purification and is chosen by globally recognized brands due to this product differentiation."
"The Financial Times, the leading UK financial publication, recently ranked Cellarius as one of Europe’s fastest growing companies."
https://ih.advfn.com/stock-market/NASDAQ/applied-uv-AUVI/stock-news/88412681/applied-uv-receives-substantial-order-from-europea
Links to FT list 2022
Special Report
FT 1000: Europe’s Fastest Growing Companies
The latest annual list of businesses by revenue growth puts a Finnish seller of used mobile phones at the top. Explore the 2022 interactive ranking here."
https://www.ft.com/reports/europes-fastest-growing-companies
https://www.ft.com/ft1000-2022
Click "show more" after Top 50
Cellarius ranks 788 / 1000
Click Cellarius hot link to:
https://cellarius.hu/
$AUVI
HUSA 06-16 Float 8.83MM / 03-31 Cash $4,766,887. Sources: Marketwatch / SEC 10-Q, respectively.
https://www.marketwatch.com/investing/stock/husa
Drilling operations on Houston American’s first well in the CPO-11 Block Venus Exploration are ongoing since end of May in the Llanos Basin, Colombia. (PR)
"The LLanos Basin is the most prolific hydrocarbon basin of Colombia, hosting well-known petroleum deposits as Caño Limón, Rubiales and other fields. Nine of the twenty most producing oil fields of Colombia are situated in the Llanos Basin." Wiki
HUSA as only a proxy for oil-price misses the mark, in my view. The world runs on oil. There are 195 countries and 8 billion people as of June 2022; 99+% of them depend on oil one way or the other. Demand is unrelenting in the face of tight suppplies. HUSA doesn't live or die with each tick of the oil price. Overlooked by eyes glued to WTI is HUSA as also an oil, gas & mineral exploration company with international and domestic properties. The Colombian property in an oil rich basin, for example, on which spudding began at the end of May is potentially a game changer.
https://www.wsj.com/articles/oil-supply-growth-expected-to-lag-behind-demand-next-year-11655282445
$HUSA
05-24-2022 Houston American Energy announces spudding of first well on CPO-11 Venus Exploration Area in Colombia, South America. See map.
Ps. Houston American holds approximately 11% interest in the CPO-11 Venus Exploration area and approximately 5.5% interest in remainder of the block. Drilling operations on Houston American’s first well in Venus Exploration area ongoing from May 24, 2002.
$HUSA
Yes. No debt, millions in cash, mini-float, staggering prospects.
E.g., "Drilling operations on Houston American’s first well in the Venus Exploration are ongoing* (at least since May 2022) in the Llanos Basin, "the most prolific hydrocarbon basin of Colombia, hosting well-known petroleum deposits as Caño Limón, Rubiales and other fields. Nine of the twenty most producing oil fields of Colombia are situated in the Llanos Basin." (quoting Wilkipedia)
HUSA is a small cat now, but may roar like a lion before long.
GIANT Oil and Nat Gas fields: 500 million barrels (79,000,000 m3) of recoverable oil or natural gas equivalent
1) Boral-1 Field, Colombia, Discovered 2008, Giant Field
2) Cano Limon Field, Colombia, Discovered 1983, Giant Field
3) Chuchupa Field, Colombia, Discovered 1973, Giant Field
4) Cupiagua Field, Colombia, Discovered 1993, Giant Field
5) Cusiana Field, Colombia, Discovered 1992, Giant Field
6) La Cira-Infantas Field, Colombia, Discovered 1918, Giant Field
7) Opon Field, Colombia, Discovered 1956, Giant Field
8) Volcanera Field, Colombia, Discovered 1993, Giant Field
https://www.cccarto.com/oil/colombiaoil/#4/7.62/-93.96
*Houston, TX, May 27, 2022 (GLOBE NEWSWIRE) --Houston American Energy Corp. (NYSE American: HUSA) today announced the acquisition of an additional interest in Hupecol Meta, LLC. Hupecol Meta owns the 639,405 gross acre CPO-11 block in the Llanos Basin in Colombia, comprised of the 69,128 acre Venus Exploration area, operated by Hupecol, and 570,277 acres which was 50% farmed out to Parex Resources by Hupecol. In total, the CPO-11 block covers almost 1000 square miles with multiple identified leads and prospects expected to support a multi-well drilling program. Through its membership interest in Hupecol Meta, Houston American now holds an approximately 11% interest in the Venus Exploration area and an approximately 5.5% interest in the remainder of the block. Drilling operations on Houston American’s first well in the Venus Exploration area are now ongoing. End quote.
"Based in Houston, Texas, Houston American Energy Corp. is a publicly-traded independent energy company with interests in oil and natural gas wells, minerals and prospects. The Company's business strategy includes a property mix of producing and non-producing assets with a focus on the Delaware Basin in Texas and Colombia."
https://houstonamerican.com/
$HUSA NYSEAmerican Exchange
$HUSA Fed rate hike already priced in. Substantive increase telegraphed well in advance. Market hates clouds of uncertainty, hence, look for a rebound after this cloud passes. Forward look to oil-rich Colombia fields.
$HUSA Rumblings from Colombia?
Go TPOXX! Reuters:Monkeypox DNA Found in Semen 6-13-2022
https://www.usnews.com/news/top-news/articles/2022-06-13/monkeypox-dna-found-in-semen-in-handful-of-cases-researchers-say
$SIGA
$SIGA TPOXX the only safe&approved treatment for Monkeypox. It's also labelled for treatment of complications caused from that sole vaccine--with the numerous listed side efffects and warnings--made in Denmark.
Low float
New BAVA vaccine delayed in production to 2023 (factory shut for overhaul) + MPX cases mounting+ Pride month spread + vaccine distrust/hesitancy = a run on approved safe anti-viral TPOXX®.
SIGA @ bargain price currently.
"The drug [Tecovirimat a/k/a TPOXX] traps the virus within the infected cell so it can't spread, but it still lets the immune system react to the viral antigens attacking the body," Dr. Dennis Hruby (Chief Scientific Officer of Siga) explained.
Our drug will stop further progression of the disease and then allow your natural immune system to kick in and eradicate the virus,” Hruby said in an interview.
https://www.euronews.com/next/2022/05/20/monkeypox-outbreak-drugmaker-siga-says-eu-authorities-seeking-to-stockpile-its-smallpox-an
Siga's Dr. Hruby: "We have tested it [TPOXX] extensively against monkeypox because monkeypox in non-human primates was the primary animal model that supported its approval. So, we know it works; it works very well. It protects virtually every monkey that is treated. And we can give the drug quite late in the progression of the disease (ed.: i.e., even after lesions manifest 14-17 days after initial infection) and still protect (ed.: compare to 1-4 day window for Bavarian Nordic vaccine)."
"We've had the oppportunity to use the drug in a number in compassionate use cases over the years in people infected with vaccinia, with cowpox, and more recently with monkeypox, and seen good outcomes in ALL cases. So, we are confident the drug will be quite effective against monkeypox in humans."
"We saw no severe adverse events in clinical trials with humans. Any adverse events we saw were typical and about the same rate as placebo. We've seen nothing that would give us the safety signal. There are no contraindications."
"[W]e believe the drug could be used for post exposure prophylaxis (protection). [...] We have done that in animal models; we are quite confident it will work."
https://www.contagionlive.com/view/a-potential-monkeypox-therapy-
SIGA Partners (Siga Tech Inc. In business for 25 years. Profitable healthy firm w/US$156Million cash hoard and pays a dividend.)
$SIGA
Hruby said TPOXX is effective against all orthopoxviruses.* Such a feat should qualify the inventor for a Nobel Prize in Medicine. It may yet happen that way when TPOXX is hailed far and wide as a timely wonder drug. Close-contact mass superspreader events are taking place this month all around the world--inviting an inevitable logarithmic spike in cases and a virtual warranty of endemic monkeypox outbreaks for years to come in a large swath of the globe hitherto not affected.
Dr. Hruby: "We protected virtually every animal we treated when infected with a pox virus. [...] It is approved in Europe for treatment of all orthopoxviruses." June 10, 202
https://www.contagionlive.com/view/a-potential-monkeypox-therapy-
*Genus Orthopoxvirus includes Abatino macacapox virus, Akhmeta virus, Alaskapox virus, Camelpox virus, Cowpox virus, Ectromelia virus, Monkeypox virus, Raccoonpox virus, Skunkpox virus, Taterapox virus, Vaccinia virus †Variola virus (smallpox), Volepox virus. [Wikipedia]
Siga Partners
$SIGA
Dr. Hruby: "We have tested it [TPOXX] extensively against monkeypox because monkeypox in non-human primates was the primary animal model that supported its approval. So, we know it works; it works very well. It protects virtually every monkey that is treated. And we can give the drug quite late in the progression of the disease (ed.: i.e., even after lesions manifest 14-17 days after initial infection) and still protect (ed.: compare to 1-4 day window for Bavarian Nordic vaccine)."
"We've had the oppportunity to use the drug in a number in compassionate use cases over the years in people infected with vaccinia, with cowpox, and more recently with monkeypox, and seen good outcomes in ALL cases. So, we are confident the drug will be quite effective against monkeypox in humans."
"We saw no severe adverse events in clinical trials with humans. Any adverse events we saw were typical and about the same rate as placebo. We've seen nothing that would give us the safety signal. There are no contraindications."
"[W]e believe the drug could be used for post exposure prophylaxis (protection). [...] We have done that in animal models; we are quite confident it will work."
Excerpts June 10, 2022
https://www.contagionlive.com/view/a-potential-monkeypox-therapy-
$SIGA
Currrent share price US$9.65
Dr. Hruby: "[W]ith the emerging disease problem, we are getting a lot of requests both from governments and from hospitals treating patients. I can't go into details, but we are working very hard to supply the drug to those that need it, and get it into hands of governments for dispersal." June 10, 2022
https://www.contagionlive.com/view/a-potential-monkeypox-therapy-
SIGA Partners
$SIGA
$SIGA TPOXX The only treatment for monkeypox AND for complications from the dicey monkeypox vaccine.
Catch the bargain price.
FDA approved anti-viral TPOXX
Siga Technologies, Inc. is an extremely well-connected & solvent dividend-paying profit maker in business for 25 years.
https://investorshub.advfn.com/Siga-Technologies-Inc-SIGA-6976
Dr. Hruby: "Our drug (TPOXX) will stop further progression of the disease [monkeypox], and then allow your natural immune system to kick in and eradicate the virus. The drug traps the virus within the infected cell so it can't spread, but it still lets the immune system react to the viral antigens attacking the body."
SIGA Partners
Transcript of Dr. Hruby's interview June 10, 2022.
Dr. Hruby currently serves as Executive Vice President and Chief Scientific Officer, having served as SIGA's Chief Scientific Officer since 2000.
Video link (6 minutes)
https://www.contagionlive.com/view/a-potential-monkeypox-therapy-
Transcript
Dr. Hruby: TPOXX was a drug developed under U.S. federal sponsorship to prevent or treat smallpox. It is a drug that is an egress inhibitor; it works against ALL orthopoxviruses both in vitro (in glass) and in animal models.
We have tested it extensively against monkeypox because monkeypox in non-human primates was the primary animal model that supported its approval. So, we know its works; it works very well. It protects virtually every monkey that is treated. And we can give the drug quite late in the progression of the disease and still protect (ed. only a 1-4 day interval for Bavarian Nordic vaccine). We've had the oppportunity to use the drug in a number in compassionate use cases over the years in people infected with vaccinia, with cowpox, and more recently with monkeypox, and seen good outcomes in ALL cases. So, we are confident the drug will be quite effective against monkeypox in humans.
-Question about efficacy & safety profile of the drug.
Dr. Hruby: The efficacy is quite high. I mean, we've protected virtually every animal we treated when infected with a pox virus. One of the challenges is that pox viruses like monkeypox have relatively long incubation periods, 10 to 14 days before you start elaborating the symptoms. The first symptoms are typically headache, flu-like symptoms, and then lesions will elaborate in about 14 to 17 days. Certainly, in non-human primates (monkeys, e.g.) we can give the drug even after lesions of the disease have erupted, and still save them. Obviously, if you treated earlier in the course of infection, you will have even a greater effect on the outcome of the disease.
As far as safety profile, so far it has been really, really excellent. We saw no severe adverse events in clinical trials with humans. Any adverse events we saw were typical and about the same rate as placebo. We've seen nothing that would give us the safety signal. There are no contraindications. One of the reasons for that is the target of the drug and the virus is not conserved in the host. And so there are not other enzymes in the host that this drug is hitting. For that reason, it seems to be remarkably safe.
Certainly, you might imagine that with the emerging disease problem, we are getting a lot of requests both from governments and from hospitals treating patients. I can't go into details, but we are working very hard to supply the drug to those that need it, and get it into hands of governments for dispersal.
-Q: For those who do have the virus, the monkeypox virus, what is the typical dosing for the therapy?
Dr. Hruby :The therapy as it is approved, and I point out that it's approved in the U.S. for treatment of smallpox. It is approved in Europe for treatment of all orthopoxviruses including monkeypox. In either case, the therapy is an oral drug. You take three capsules twice day for 14 days. We also have the intravenous (IV) formulation of this drug approved in recently in the U.S., and that's another possibility if someone should have a very advanced disease and be hospitalized.
-Q: Is there an optimal timing to begin the therapies to enable best effficacy?
Dr. Hruby: Despite an earlier answer, the earlier the better, we believe the drug could be used for post exposure prophylaxis (protection). I give it to people who have not been exposed or in early stages of incubating the virus. Here in the U.S. we are supported by the Department of Defense to do clinical work to do post exposure prophylaxis [PEP]. We have done that in animal models; we are quite confident it will work. It's an area we have to demonstrate for regulatory approval.
- Question regarding Siga's delivery of drug to U.S. Strategic Stockpile
Dr. Hruby: We were originally contracted to supply 1.7 million courses (course= daily dose for 14 days) of oral therapy to the U.S. Strategic National Stockpile. That is the amount of drug they currently have on hand. We now have a contract to maintain that amount of drug in the stockpile. So, as the drug expires, we are supplying the U.S. government with additional drug so we have steady state supply here in the U.S.
If it had been a longer interview, Hruby would have had time to mention that anti-viral TPOXX is also labeled in Europe to treat complications from the existing smallpox vaccines.
$SIGA
Not What if? now, but When? Rat population. "If the pox currently circulating in the U.S. spreads to rats, hamsters, or gerbils, and becomes endemic in those species, there might be no easy way to contain it. “I do share the other scientists’ concern of containment and the virus becoming endemic in our U.S. rodent population,” sys Stephanie James, the head of a viral testing lab at Regis University in Colorado."
https://www.rollingstone.com/culture/culture-features/monkeypox-outbreak-two-strains-pets-rats-1366935/amp/
$SIGA
6-10-Stunning interview w/Dr. Hruby. In sum, TPOXX rules. 6 minutes long. Amazing info supporting TPOXX as a wonder drug.
https://www.contagionlive.com/view/a-potential-monkeypox-therapy-
Transcript
Dr. Hruby*: TPOXX was a drug developed under U.S. federal sponsorship to prevent or treat smallpox. It is a drug that is an egress inhibitor; it works against ALL orthopoxviruses both in vitro (in glass) and in animal models.
We have tested it extensively against monkeypox because monkeypox in non-human primates was the primary animal model that supported its approval. So, we know its works; it works very well. It protects virtually every monkey that is treated. And we can give the drug quite late in the progression of the disease and still protect. (ed. 1-4 days for Bava vaccine) We've had the oppportunity to use the drug in a number in compassionate use cases over the years in people infected with vaccinia, with cowpox, and more recently with monkeypox, and seen good outcomes in ALL cases. So, we are confident the drug will be quite effective against monkeypox in humans.
-Question about efficacy & safety profile of the drug.
Dr. Hruby: The efficacy is quite high. I mean, we've protected virtually every animal we treated when infected with a pox virus. One of the challenges is that pox viruses like monkeypox have relatively long incubation periods, 10 to 14 days before you start elaborating the symptoms. The first symptoms are typically headache, flu-like symptoms, and then lesions will elaborate in about 14 to 17 days. Certainly, in non-human primates (monkeys, e.g.) we can give the drug even after lesions of the disease have erupted, and still save them. Obviously, even if you treated earlier in the course of infection, you will have even a greater effect on the outcome of the disease.
As far as safety profile, so far it has been really, really excellent. We saw no severe adverse events in clinical trials with humans. Any adverse events we saw were typical and about the same rate as placebo. We've seen nothing that would give us the safety signal. There are no contraindications. One of the reasons for that is the target of the drug and the virus is not conserved in the host. And so there are not other enzymes in the host that this drug is hitting. For that reason, it seems to be remarkably safe.
Certainly, you might imagine that with the emerging disease problem, we are getting a lot of requests both from governments and from hospitals treating patients. I can't go into details, but we are working very hard to supply the drug to those that need it, and get it into hands of governments for dispersal.
-Q: For those who do have the virus, the monkeypox virus, what is the typical dosing for the therapy?
Dr. Hruby :The therapy as it is approved, and I point out that it's approved in the U.S. for treatment of smallpox. It is approved in Europe for treatment of all orthopoxviruses including monkeypox. In either case, the therapy is an oral drug. You take three capsules twice day for 14 days. We also have the IV (intravenous) formulation of this drug approved in recently in the U.S., and that's another possibility is someone should have a very advanced disease and be hospitalized.
-Q: Is there an optimal timing to begin the therapies to enable best effficacy?
Dr. Hruby: Despite an earlier answer, the earlier the better, we believe the drug could be used for post exposure prophylaxis (protection). I give it to people who have not been exposed or in early stages of incubating the virus. Here in the U.S. we are supported by the Department of Defense to do clinical work to do post exposure prophylaxis [PEP]. We have done that in animal models; we are quite confident it will work. It's an area we have to demonstrate for regulatory approval.
- Question regarding Siga's delivery of drug to U.S. Strategic Stockpile
Dr. Hruby: We were originally contracted to supply 1.7 million courses (course= daily dose for 14 days) of oral therapy to the U.S. Strategic National Stockpile. That is the amount of drug they currently have on hand. We now have a contract to maintain that amount of drug in the stockpile. So, as the drug expires, we are supplying the U.S. government with additional drug so we have steady state supply here in the U.S.
Had it been longer Hruby would have had time to mention that anti-viral TPOXX is also labled in Europe to treat complications from the vaccine.
*Dr. Hruby currently serves as Executive Vice President and Chief Scientific Officer, having served as SIGA's Chief Scientific Officer since 2000.
$SIGA
BAVA stymied+cases mounting+Pride month+vaccine distrust/hesitancy = a run on approved safe anti-viral TPOXX®.*
(Stark offputting warnings on the two rival drugs are concerning for liver damage and renal [kidney] failure.)
-The drug [Tecovirimat a/k/a TPOXX] “traps the virus within the infected cell so it can't spread” but it still lets the immune system react to the viral antigens attacking the body," Dr. Dennis Hruby (Chief Scientific Officer of Siga) explained.
-Our drug will stop further progression of the disease and then allow your natural immune system to kick in and eradicate the virus,” Hruby** said in an interview.
https://www.euronews.com/next/2022/05/20/monkeypox-outbreak-drugmaker-siga-says-eu-authorities-seeking-to-stockpile-its-smallpox-an
Note: TPOXX is also labeled for the complications attendant to orthopoxvirus vaccination.
"Oral tecovirimat received approval from the European Medicines Agency (EMA) in 2022. The EMA approval (also) includes labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox."
https://finance.yahoo.com/news/siga-announces-start-tpoxx-post-123000478.html
*-TPOXX anti-viral drug is safe enough for clinicians to treat monkeypox-infected patients of all ages including pregnant or breastfeeding women per CDC EA-IND. A high standard of safety.
-Furthermore, per CDC, the only people ineligible for Tecovirimat (TPOXX) treatment under the EA-IND include:
1) Patients (or their legally authorized representatives) who are unwilling to sign an informed consent and refuse Tecovirimat treatment
2) Patients with known allergy to Tecovirimat and/or excipients of Tecovirimat
https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html
-No contraindications reported.
**Dennis Hruby, Ph.D., is a distinguished scientist with more than 25 years of experience in poxviruses, virology, and anti-infective research. Dr. Hruby currently serves as Executive Vice President and Chief Scientific Officer, having served as SIGA's Chief Scientific Officer since 2000.
$SIGA
"Science" (10 June '22 issue): "Euro clade"? "Typically, monkeypox outbreaks occur in Africa when the virus spills over from animal species—most commonly rodents, not monkeys—that regularly infect each other and act as reservoirs for the pathogen. But no links to animals have been found in cases of the current outbreak, and the first patients surfaced in Europe, where increasing evidence suggests the virus may have been transmitting between humans undetected for many months."
"...some researchers argue the human strains now being seen around the world actually form a third clade, and those viruses may also have different transmission characteristics."
“It’s quite clear that this virus is related in a very different way” to previously sequenced strains, says Tulio de Oliveira, an evolutionary biologist at the University of KwaZulu-Natal who is last author of the preprint.
“There was a big adaptation to the human host. The real source of this outbreak is mostly Europe and then it is being introduced everywhere else in the world,” Oliveira says.
https://www.science.org/content/article/rename-monkeypox-remove-geographic-stigma-researchers-say
$SIGMA
Bouncing Tom to new boss Altaris: "However you slice it, guys, vaccine or no vaccine, safe anti-viral TPOXX is on the menu of treatment for orthopoxviruses."
"Oral tecovirimat (TPOXX) received approval from the European Medicines Agency (EMA) in 2022. The EMA approval (also) includes labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox."
https://finance.yahoo.com/news/siga-announces-start-tpoxx-post-123000478.html
$SIGA
SIGA plot thickens as Altaris acquires Meridian Medical Technologies, LLC--a Pfizer company.
Item 1:
"Altaris Acquires Meridian Medical Technologies (LLC) from Pfizer"
https://www.meridianmeds.com/ (Tom Handel - Chief Commercial Officer)
"For over 60 years, Meridian Medical Technologies, LLC has been supporting the development, production, and commercialization of acute and chronic care pharmaceuticals administered through advanced, proprietary auto-injector technology. As one of the few companies in the world offering both sterile filling and auto-injector capabilities, our mission is to be the premier contract development and manufacturing organization (CDMO) for complex sterile drug products and the ideal strategic partner for the health securities, emergency response, and pharmaceutical industries."
Item 2: SIGA PR dated June 3, 2019
"SIGA Announces TPOXX® Promotion Agreement with Meridian Medical Technologies, Inc. (A Pfizer Company) for International Markets"
“TPOXX is a natural addition to Meridian’s portfolio of medical countermeasures and emergency care treatments,” said Tom Handel, General Manager for Pfizer and President of Meridian. “We are excited to partner with SIGA to leverage our collective strengths for the ultimate benefit of global health security, the patients and customers who we serve.”
https://investor.siga.com/news-releases/news-release-details/siga-announces-tpoxxr-promotion-agreement-meridian-medical
Note: The hyper-acquisitve "Altaris Capital Partners, LLC is an investment firm focused exclusively on the healthcare industry. Altaris is based in New York and actively manages $5.0 billion of equity capital. [...] Since inception in 2003, we have invested in more than 40 healthcare companies (43) that have contributed to advancements in the industry and generated significant value appreciation for our investors. [...] We target businesses that we believe address the needs of the healthcare system by improving patient outcomes, eliminating unnecessary costs, increasing efficiency and aligning stakeholder incentives. Our areas of focus span the major verticals of the industry, including companies that operate in the pharmaceutical, medical device, provider services and healthcare insurance subsectors."
https://altariscap.com/
Altaris Capital Partners, LLC Portfolio of companies as of June 2022
Meridian Medical Technologies is listed as one the 43 firms in their stable.
$SIGA
Bavarian Nordic--MPX vaccine maker has a big problem.
"Bavarian Nordic which is based in Denmark, increased its 2022 revenue guidance after an international outbreak of monkeypox in May. But the plant where the company makes the vaccine is shut down until August to expand it, and management estimates it will takes six months—until early next year— to have any new doses once manufacturing has restarted."
https://www.barrons.com/articles/monkeypox-vaccine-maker-plant-delay-51654789708
Conclusion: Siga is going to be deluged with orders for its anti-viral TPOXX (tecovirimat), the go-to safe treatment that stops the monkeypox virus from replicating and allows the body's immune system to eradicate the virus.
The drug “traps the virus within the infected cell so it can't spread” but it still lets the immune system react to the viral antigens attacking the body, Dr. Hruby explained.
Our drug will stop further progression of the disease and then allow your natural immune system to kick in and eradicate the virus,” Hruby said in an interview.
https://www.euronews.com/next/2022/05/20/monkeypox-outbreak-drugmaker-siga-says-eu-authorities-seeking-to-stockpile-its-smallpox-an
https://www.drugs.com/search.php?searchterm=TPOXX&a=1
No warnings or contraindications reported. (i.e., very safe)
$SIGA
Peerless and safe. Dr. Hruby: "Our drug (TPOXX) will stop further progression of the disease [monkeypox], and then allow your natural immune system to kick in and eradicate the virus,” Hruby said in an interview. “
The drug “traps the virus within the infected cell so it can't spread” but it still lets the immune system react to the viral antigens attacking the body, he explained.
https://www.euronews.com/next/2022/05/20/monkeypox-outbreak-drugmaker-siga-says-eu-authorities-seeking-to-stockpile-its-smallpox-an
CDC seal of approval for use by clinicians: CDC EA-IND protocol allows the use of tecovirimat for primary or early empiric treatment of non-variola orthopoxvirus infections, including monkeypox, in adults and children of all ages.
-The only people ineligible for tecovirimat treatment under the EA-IND include:
1) Patients (or their legally authorized representatives) who are unwilling to sign an informed consent and refuse tecovirimat treatment
2) Patients with known allergy to tecovirimat and/or excipients of tecovirimat
https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html
(i.e., very few)
https://www.drugs.com/search.php?searchterm=TPOXX&a=1
No warnings or contraindications reported. (i.e., very safe)
$SIGA
Ps. Dr. Dennis Hruby, is chief scientific officer at SIGA Technologies, Inc. [a firm 25 years in business]
"Dennis E. Hruby, Ph.D. - SIGA: Human BioArmor
Dennis Hruby, Ph.D. is a distinguished scientist with more than 25 years of experience in poxviruses, virology, and anti-infective research. Dr. Hruby currently serves as Executive Vice President and Chief Scientific Officer, having served as SIGA's Chief Scientific Officer since 2000."
TPOXX® vs.Vaccine. An overlooked bombshell by Dr. Hruby. (q.v.) Also attached below: Mayo Clinic weighs in on the vaccine; in sum, problematic may be a gross understatement or put differently, feel lucky?
Excerpt from Euronews.next (May 20, 2022): "Monkeypox outbreak: Drugmaker SIGA says EU authorities seeking to stockpile its smallpox antiviral"
Quote
"As you might imagine, a number of the jurisdictions where cases are being found have contacted us and are interested in acquiring the drug as soon as possible,” Dennis Hruby, chief scientific officer at SIGA Technologies, told Euronews Next on Friday.
How does tecovirimat [anti-viral TPOXX] fight monkeypox?
“Our drug will stop further progression of the disease and then allow your natural immune system to kick in and eradicate the virus,” Hruby said in an interview.
The drug “traps the virus within the infected cell so it can't spread” but it still lets the immune system react to the viral antigens attacking the body, he explained.
“So that while you're on the drug and hopefully being saved from further disease, you're also arming your immune system and getting a protective immune response," Hruby added. [i.e., PEP / prophylactic effect]
https://www.euronews.com/next/2022/05/20/monkeypox-outbreak-drugmaker-siga-says-eu-authorities-seeking-to-stockpile-its-smallpox-an
Compare TPOXX (CDC: No warnings or contradications) to Jynneos vaccine with the latter's known adverse side effects per the Mayo Clinic.
Quote
1) "In deciding to use a vaccine, the risks of taking the vaccine must be weighed against the good it will do."
2) "Appropriate studies have not been performed on the relationship of age to the effects of smallpox monkeypox vaccine, live non-replicating, in the pediatric population. Safety and efficacy have not been established."
3) "Appropriate studies have not been performed on the relationship of age to the effects of smallpox monkeypox vaccine, live non-replicating in the elderly 65 years of age and older. Safety and efficacy have not been established."
4) "There are no adequate studies in women for determining infant risk when using this medication during breastfeeding."
5) "It is very important that you receive the second dose of the vaccine series..."
6) "This vaccine may cause a serious allergic reaction, including anaphylaxis, which can be life-threatening and requires immediate medical attention. Call your doctor right away if you have a rash, itching, hoarseness, trouble breathing, trouble swallowing, or any swelling of your hands, face, or mouth after you receive the vaccine.
7) Listed known side effects:
"Chills, cough, difficulty with swallowing, dizziness, fast heartbeat, hives, itching, rash, puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue, tightness in the chest, troubled breathing, unusual tiredness or weakness, bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site, headache, muscle pai, nausea."
9) "This vaccine may not protect everyone who receives it." [the punchline]
https://www.mayoclinic.org/drugs-supplements/smallpox-monkeypox-vaccine-live-non-replicating-subcutaneous-route/side-effects/drg-20473664?p=1
$SIGA
What if? ... In Africa, monkeypox spreads to humans by way of infected rodents such as rats, squirrels, and monkeys with whom the human inhabitants of low-density Central and West Africa live in close proximity.
High-density urban centers in Europe, the New World, and Asia are home to countless numbers of rodents. A 2014 scientific study estimated that 2 milllion rats (the 4-legged kind) infest New York City alone. What if monkeypox virus jumped from an infected human urbanite to a rat thence rat to rat ad libitum? A bit of a problem in containment.
Scientific American 2003
$SIGA
TPOXX trounces the competition. No sane person with a yen for living would resort to those two highly toxic rival drugs in lieu of Siga's TPOXX® .
Rival #1 Brincidofovir (Tembexa brand name, U.S.)
1) "Warning: Increased Risk for Mortality [i.e., Death] When Used for Longer Duration - An increased incidence of mortality was seen in brincidofovir-treated subjects compared to placebo-treated subjects in a 24-week clinical trial when brincidofovir was evaluated in another disease."
2) "Brincidofovir may cause serious liver problems."
3) "Using brincidofovir while you are pregnant can harm your unborn baby."
4) "Some men who use brincidofovir have become infertile (unable to have children)."
5) "Check with your doctor right away if you have diarrhea, nausea, vomiting, or stomach pain. These could be symptoms of a serious stomach or bowel problem."
https://www.drugs.com/cons/brincidofovir.html
Rival #2 Cidofovir Injection (Vistide, brand name)
1) "Warning: RENAL [kidney] IMPAIRMENT IS THE MAJOR TOXICITY OF Cidofovir Injection. CASES OF ACUTE RENAL [kidney] FAILURE RESULTING IN DIALYSIS AND/OR CONTRIBUTING TO DEATH HAVE OCCURRED WITH AS FEW AS ONE OR TWO DOSES OF Cidofovir Injection."
2) "IN ANIMAL STUDIES CIDOFOVIR WAS CARCINOGENIC, TERATOGENIC AND CAUSED HYPOSPERMIA [Infertility] (SEE CARCINOGENESIS, MUTAGENESIS, & IMPAIRMENT OF FERTILITY)."
(Caps theirs)
https://www.drugs.com/pro/cidofovir-injection.html
Compare to Siga's TPOXX
https://www.drugs.com/search.php?searchterm=TPOXX&a=1
No warnings or contraindications reported.
$SIGA
"I love monopolies" -Warren Buffett. Siga holds a de facto monopoly on the safe treatment of monkeypox, cowpox, smallpox, and complications from vaccination for smallpox. Siga's approved drug TPOXX has but two rivals. Warnings on those two rival drugs relate to their causing damage to the liver and/or kidneys. TPOXX carries no such warnings or any other contraindications, for that matter. Thus, in reality, there is only one approved safe treatment (with a prophylactic kick) of monkeypox disease.
$SIGMA
Watch for US-FDA EUA of TPOXX® for monkeypox. Anti-viral TPOXX Oral & IV are already fully FDA approved for smallpox. Since the US CDC has given an unreserved seal of approval to health providers to use TPOXX (tecovirimat) to treat monkeypox,* one should expect the FDA to follow with an EUA (emergency use authorization), especially, as cases of contagious monkeypox increase in the USA. There's no medical or scientifc reason not to grant that request.
Furthermore, "Tecovirimat (TPOXX) was approved by the European Medicines Agency (EMA) in January 2022 with a broader label that covers the treatment of smallpox, monkeypox, cowpox, and complications from vaccination for smallpox."
https://www.globenewswire.com/news-release/2022/05/12/2442467/9738/en/New-Contract-Awarded-by-U-S-Department-of-Defense-for-the-Procurement-of-up-to-Approximately-7-5-Million-of-Oral-TPOXX.html
Wikipedia: "The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of medicinal products.
* https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html
$SIGA
Mystery case. No known connection to other cases.
Published June 7, 2022 8:10 p.m. EDT
Edmonton, Alberta, Canada
A second case of monkeypox has been identified in Alberta, Chief Medical Officer of Health Dr. Deena Hinshaw announced on Tuesday.
In a series of tweets, Hinshaw said the patient is self-isolating and has been working with the province on contact tracing efforts.
“While we will not provide identifying information to protect the privacy of this adult, I can confirm that this case is not linked to the first case announced last week, and at this time there is no known direct connection to other confirmed cases,” she wrote.
Hinshaw said monkeypox transmits through skin-to-skin contact, and can be spread to sexual partners.
“While monkeypox is not an STI [sexually transmitted infection], the majority of global cases to date have been among men who have reported intimate relations w/other men,” she wrote.
“This does not mean monkeypox is limited to one community. Anyone with prolonged close contact with someone who is infectious is at risk and it is important to not stigmatize any group. Advice to practice safer sex applies to everyone, such as avoiding having sex if feeling unwell.”
Anyone with symptoms such as genital sores, fever, or rash, especially in those who have had contact with a new sexual partner, is asked to self-isolate and call 811.
End quote
https://edmonton.ctvnews.ca/second-case-of-monkeypox-confirmed-in-alberta-1.5937300
$SIGA
CDC: "Tecovirimat (TPOXX) may be considered for treatment in people infected with Monkeypox virus:
1) With severe disease (e.g., hemorrhagic disease, confluent lesions, sepsis, encephalitis, or other conditions requiring hospitalization)
2) Who are at high risk of severe disease:
a) People with immunocompromising conditions (e.g., HIV/AIDS, leukemia, lymphoma, generalized malignancy, solid organ transplantation, therapy with alkylating agents, antimetabolites, radiation, tumor necrosis factor inhibitors, high-dose corticosteroids, being a recipient with hematopoietic stem cell transplant <24 months post-transplant or ≥24 months but with graft-versus-host disease or disease relapse, or having autoimmune disease with immunodeficiency as a clinical component
b) Pediatric populations, particularly patients younger than 8 years of age
c) Pregnant or breastfeeding women
d) People with one or more complication (e.g., secondary bacterial skin infection; gastroenteritis with severe nausea/vomiting, diarrhea, or dehydration; broncho-pneumonia; concurrent disease or other comorbidities)
3) With aberrant infections involving accidental implantation in eyes, mouth, or other anatomic areas where Monkeypox virus infection might constitute a special hazard (e.g., the genitals or anus)
End quote
Nota bene: TPOXX anti-viral drug is safe enough to treat patients of all ages and pregnant or breastfeeding women. That's an extremely high standard of safety.
https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html
$SIGA
Impressive advocacy. CDC is all in for TPOXX as primary and empiric treatment of diseases wrought by Orthopoxvirus genus (monkeypox et alii).
https://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html
$SIGA